Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CTSS | P25774 | 1/20 | 0.35 |
| ▸ | CTSK | P43235 | 1/20 | 0.35 |
| ▸ | CTSC | P53634 | 1/20 | 0.34 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | ECE1 | P42892 | 1/20 | 0.33 |
| ▸ | F10 | P00742 | 2/20 | 0.32 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7200310 | 1.00 | KMT2A (0.38) | KMT2APOLBLMNACTSSCTSK | |
| SCHEMBL27739908 | 0.86 | LMNA (0.47) | KMT2APOLBLMNACTSSCTSK | |
| SCHEMBL29355019 | 0.86 | LMNA (0.47) | KMT2APOLBLMNACTSSCTSK | |
| SCHEMBL27739903 | 0.86 | LMNA (0.47) | KMT2APOLBLMNACTSSCTSK | |
| SCHEMBL23764912 | 0.85 | — | — | |
| SCHEMBL15840471 | 0.85 | KMT2A (0.37) | KMT2APOLBLMNACTSSCTSK | |
| SCHEMBL23774717 | 0.85 | — | — | |
| SCHEMBL29374394 | 0.82 | TPSAB1 (0.33) | LMNACTSCOPRD1ECE1PRSS1 | |
| SCHEMBL22829568 | 0.82 | KMT2A (0.47) | KMT2APOLBLMNACTSSCTSK | |
| SCHEMBL30493612 | 0.82 | KMT2A (0.47) | KMT2APOLBLMNACTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030050242-A1 | Protein polymerization inhibitors and methods of use | TRIPEP AB (SE) | 2003-03-13 | — | — | US | disclosed |
| US-20020091086-A1 | Peptides that block viral infectivity and methods of use thereof | VAHLNE ANDERS (SE) | 2002-07-11 | — | — | US | disclosed |
| EP-1207897-A2 | PHARMACEUTICAL COMPOSITIONS CONTAINING TRIPEPTIDES | TRIPEP AB (SE) | 2002-05-29 | — | — | EP | disclosed |
| EP-1206273-A2 | PEPTIDES THAT BLOCK VIRAL INFECTIVITY AND METHODS OF USE THEREOF | TRIPEP AB (SE) | 2002-05-22 | — | — | EP | disclosed |
| US-6258932-B1 | TRIPEPTIDE OF DEFINED AMINO ACID SEQUENCE AND HAVING A C-TERMINAL AMIDE; VIRICIDES; TREATMENT AND PREVENTION OF HUMAN IMMUNODEFICIENCY VIRUS | TRIPEP AB (BE) | 2001-07-10 | — | — | US | disclosed |
| WO-2001010457-A2 | PHARMACEUTICAL COMPOSITIONS CONTAINING TRIPEPTIDES | TRIPEP AB (SE) | 2001-02-15 | — | — | WO | disclosed |
| WO-2001010456-A2 | PEPTIDES THAT BLOCK VIRAL INFECTIVITY AND METHODS OF USE THEREOF | TRIPEP AB (SE) | 2001-02-15 | — | — | WO | disclosed |